Trial Profile
Potential synergistic effects of bisphosphonates with sorafenib on renal cell carcinoma with bone metastases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Clodronic acid; Zoledronic acid
- Indications Bone metastases; Renal cell carcinoma
- Focus Therapeutic Use
- 17 Aug 2015 New trial record